Session 1: International Medical Evidence (WD-ME)
Bita Esmaeli, MD will be coordinating this session. ISOO members will be made aware of all the international multicenter projects that have been completed, those in progress, and others just starting.
There now exists ongoing, multicenter international eye cancer registries for uveal melanoma, conjunctival melanoma, vitreoretinal lymphoma, eyelid carcinoma, lacrimal gland carcinoma, and ocular adnexal lymphoma. We need the medical evidence provided by these registries to improve patient care and defend our methods of diagnosis and treatment.
- 3,800 cases of intraocular melanoma were contributed from 10 sites in 4 continents. Thus far, data analysis has provided much needed medical evidence that confirmed the validity of AJCC-UICC tumor-staging and showed that failure of initial local tumor control is associated with a 6.3x hazard ratio for metastatic disease. Additional uveal melanoma publications are in the pipeline.
- 4,250 eyes from 2,125 children were contributed from 23 centers in 6 continents. Thus far, data analysis has allowed for a new and statistically proven method of RB staging that is incorporated into the 8th edition of the AJCC-UICC systems. Registry related retinoblastoma publications will be providing additional evidence-based medicine.
- >1,000 ocular adnexal lymphomas from 7 eye cancer centers around the world were collected in a Denmark based registry. This provides us with the largest material worldwide by far. Several articles have already been published and more articles are to come on the major lymphoma subtypes. This work has produced valuable information about the efficacy of different treatments with the purpose of improving prognosis for this
patient category.
- ASOPRS oncology database currently includes over 1,500 cases with s variety of orbital eyelid and conjunctival tumors; 12 centers to date (11 from US, 1 from Canada); 5 studies initiated to date; 1 publication to datel 4 abstracts with manuscripts.
Bita Esmaeli, MD will be coordinating this session. ISOO members will be made aware of all the international multicenter projects that have been completed, those in progress, and others just starting.
There now exists ongoing, multicenter international eye cancer registries for uveal melanoma, conjunctival melanoma, vitreoretinal lymphoma, eyelid carcinoma, lacrimal gland carcinoma, and ocular adnexal lymphoma. We need the medical evidence provided by these registries to improve patient care and defend our methods of diagnosis and treatment.
- 3,800 cases of intraocular melanoma were contributed from 10 sites in 4 continents. Thus far, data analysis has provided much needed medical evidence that confirmed the validity of AJCC-UICC tumor-staging and showed that failure of initial local tumor control is associated with a 6.3x hazard ratio for metastatic disease. Additional uveal melanoma publications are in the pipeline.
- 4,250 eyes from 2,125 children were contributed from 23 centers in 6 continents. Thus far, data analysis has allowed for a new and statistically proven method of RB staging that is incorporated into the 8th edition of the AJCC-UICC systems. Registry related retinoblastoma publications will be providing additional evidence-based medicine.
- >1,000 ocular adnexal lymphomas from 7 eye cancer centers around the world were collected in a Denmark based registry. This provides us with the largest material worldwide by far. Several articles have already been published and more articles are to come on the major lymphoma subtypes. This work has produced valuable information about the efficacy of different treatments with the purpose of improving prognosis for this
patient category.
- ASOPRS oncology database currently includes over 1,500 cases with s variety of orbital eyelid and conjunctival tumors; 12 centers to date (11 from US, 1 from Canada); 5 studies initiated to date; 1 publication to datel 4 abstracts with manuscripts.
|
Convenor: Dr. Bita Esmaeli
Dr. Bita Esmaeli is a Professor of Ophthalmology, MD Anderson Cancer Center, where she has had an orbital oncology and oncologic ophthalmic plastic surgery practice. Bita has developed an ongoing multi-institutional orbital oncology database registry. She will convene the database and registry section of the Working Day. There will be introductory summaries of current results, introduction of actively recruiting and proposed registries and discussion of outstanding issues. |
